fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag,...

FDA Drug Recall #D-0503-2026 — Class II — April 1, 2026

Recall Summary

Recall Number D-0503-2026
Classification Class II — Moderate risk
Date Initiated April 1, 2026
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Wells Pharma of Houston LLC
Location Houston, TX
Product Type Drugs
Quantity 4,030 IV Bags

Product Description

fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells Pharma in Houston, NDC 73702-202-02.

Reason for Recall

cGMP deviations.

Distribution Pattern

U.S. Nationwide.

Lot / Code Information

120925202022769, Expiration Date 04/09/2026, 123125202022883, Expiration Date 05/05/2026, 123125202022884, Expiration Date 05/05/2026 011226202020057, Expiration Date 05/14/2026, 011226202020058, Expiration Date 05/14/2026, 011626202020110, Expiration Date 05/20/2026 012726202020156, Expiration Date 05/28/2026. 012726202020161, Expiration Date 05/28/2026 020226202020195, Expiration Date 06/04/2026 021826202020386, Expiration Date 06/20/2026 022026202020417, Expiration Date 06/24/2026 022026202020424 Expiration Date 06/24/2026

Other Recalls from Wells Pharma of Houston LLC

Recall # Classification Product Date
D-0507-2026 Class II Ketamine Hydrochloride Injectable Solution, 50m... Apr 1, 2026
D-0506-2026 Class II fentaNYL Citrate Injectable Solution in 0.9% So... Apr 1, 2026
D-0504-2026 Class II fentaNYL Citrate injectable Solution in 0.9% So... Apr 1, 2026
D-0505-2026 Class II fentaNYL Citrate Injectable Solution, Narcotic,... Apr 1, 2026
D-0502-2026 Class II Phenylephrine Hydrochloride Injectable Solution... Apr 1, 2026

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.